Direct and indirect comparison meta-analysis demonstrates the superiority of sirolimus- versus paclitaxel-eluting stents across 5854 patients

Giuseppe G L Biondi-Zoccai, Marzia Lotrionte, Antonio Abbate, Marco Valgimigli, Luca Testa, Francesco Burzotta, Filippo Crea, Pierfrancesco Agostoni

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

There is ongoing debate to identify the most effective, safe and cost-beneficial drug-eluting stent, between the two currently approved and used devices, i.e. sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES). To date, head-to-head comparison studies of SES vs PES have been however limited by relatively small sample sizes and the low number of events typically associated with these highly effective coronary devices. To overcome the drawbacks of single trials, direct and indirect comparison meta-analyses have been designed and conducted to thoroughly compare sirolimus- vs paclitaxel eluting-stents. This article provides results of a pooled analysis of such indirect and direct comparisons, definitively demonstrating across 5854 patients the superiority of SES in comparison to PES (odds ratio 0.62 [95% confidence interval 0.50-0.75], p <0.0001 for binary angiographic restenosis, and odds ratio 0.66 [0.52-0.84], p = 0.0008 for target lesion revascularization). Indeed, such combination of direct and indirect comparisons should also be envisaged to soundly and timely appraise the next generation of drug-eluting stents.

Original languageEnglish
Pages (from-to)104-105
Number of pages2
JournalInternational Journal of Cardiology
Volume114
Issue number1
DOIs
Publication statusPublished - Jan 2 2007

Fingerprint

Sirolimus
Paclitaxel
Stents
Meta-Analysis
Drug-Eluting Stents
Odds Ratio
Equipment and Supplies
Sample Size
Confidence Intervals
Costs and Cost Analysis

Keywords

  • Drug-eluting stent
  • Meta-analysis
  • Percutaneous coronary intervention
  • Systematic review

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Direct and indirect comparison meta-analysis demonstrates the superiority of sirolimus- versus paclitaxel-eluting stents across 5854 patients. / Biondi-Zoccai, Giuseppe G L; Lotrionte, Marzia; Abbate, Antonio; Valgimigli, Marco; Testa, Luca; Burzotta, Francesco; Crea, Filippo; Agostoni, Pierfrancesco.

In: International Journal of Cardiology, Vol. 114, No. 1, 02.01.2007, p. 104-105.

Research output: Contribution to journalArticle

Biondi-Zoccai, Giuseppe G L ; Lotrionte, Marzia ; Abbate, Antonio ; Valgimigli, Marco ; Testa, Luca ; Burzotta, Francesco ; Crea, Filippo ; Agostoni, Pierfrancesco. / Direct and indirect comparison meta-analysis demonstrates the superiority of sirolimus- versus paclitaxel-eluting stents across 5854 patients. In: International Journal of Cardiology. 2007 ; Vol. 114, No. 1. pp. 104-105.
@article{0cbfca5c39104791932e55d3e73c14a9,
title = "Direct and indirect comparison meta-analysis demonstrates the superiority of sirolimus- versus paclitaxel-eluting stents across 5854 patients",
abstract = "There is ongoing debate to identify the most effective, safe and cost-beneficial drug-eluting stent, between the two currently approved and used devices, i.e. sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES). To date, head-to-head comparison studies of SES vs PES have been however limited by relatively small sample sizes and the low number of events typically associated with these highly effective coronary devices. To overcome the drawbacks of single trials, direct and indirect comparison meta-analyses have been designed and conducted to thoroughly compare sirolimus- vs paclitaxel eluting-stents. This article provides results of a pooled analysis of such indirect and direct comparisons, definitively demonstrating across 5854 patients the superiority of SES in comparison to PES (odds ratio 0.62 [95{\%} confidence interval 0.50-0.75], p <0.0001 for binary angiographic restenosis, and odds ratio 0.66 [0.52-0.84], p = 0.0008 for target lesion revascularization). Indeed, such combination of direct and indirect comparisons should also be envisaged to soundly and timely appraise the next generation of drug-eluting stents.",
keywords = "Drug-eluting stent, Meta-analysis, Percutaneous coronary intervention, Systematic review",
author = "Biondi-Zoccai, {Giuseppe G L} and Marzia Lotrionte and Antonio Abbate and Marco Valgimigli and Luca Testa and Francesco Burzotta and Filippo Crea and Pierfrancesco Agostoni",
year = "2007",
month = "1",
day = "2",
doi = "10.1016/j.ijcard.2005.11.019",
language = "English",
volume = "114",
pages = "104--105",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Direct and indirect comparison meta-analysis demonstrates the superiority of sirolimus- versus paclitaxel-eluting stents across 5854 patients

AU - Biondi-Zoccai, Giuseppe G L

AU - Lotrionte, Marzia

AU - Abbate, Antonio

AU - Valgimigli, Marco

AU - Testa, Luca

AU - Burzotta, Francesco

AU - Crea, Filippo

AU - Agostoni, Pierfrancesco

PY - 2007/1/2

Y1 - 2007/1/2

N2 - There is ongoing debate to identify the most effective, safe and cost-beneficial drug-eluting stent, between the two currently approved and used devices, i.e. sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES). To date, head-to-head comparison studies of SES vs PES have been however limited by relatively small sample sizes and the low number of events typically associated with these highly effective coronary devices. To overcome the drawbacks of single trials, direct and indirect comparison meta-analyses have been designed and conducted to thoroughly compare sirolimus- vs paclitaxel eluting-stents. This article provides results of a pooled analysis of such indirect and direct comparisons, definitively demonstrating across 5854 patients the superiority of SES in comparison to PES (odds ratio 0.62 [95% confidence interval 0.50-0.75], p <0.0001 for binary angiographic restenosis, and odds ratio 0.66 [0.52-0.84], p = 0.0008 for target lesion revascularization). Indeed, such combination of direct and indirect comparisons should also be envisaged to soundly and timely appraise the next generation of drug-eluting stents.

AB - There is ongoing debate to identify the most effective, safe and cost-beneficial drug-eluting stent, between the two currently approved and used devices, i.e. sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES). To date, head-to-head comparison studies of SES vs PES have been however limited by relatively small sample sizes and the low number of events typically associated with these highly effective coronary devices. To overcome the drawbacks of single trials, direct and indirect comparison meta-analyses have been designed and conducted to thoroughly compare sirolimus- vs paclitaxel eluting-stents. This article provides results of a pooled analysis of such indirect and direct comparisons, definitively demonstrating across 5854 patients the superiority of SES in comparison to PES (odds ratio 0.62 [95% confidence interval 0.50-0.75], p <0.0001 for binary angiographic restenosis, and odds ratio 0.66 [0.52-0.84], p = 0.0008 for target lesion revascularization). Indeed, such combination of direct and indirect comparisons should also be envisaged to soundly and timely appraise the next generation of drug-eluting stents.

KW - Drug-eluting stent

KW - Meta-analysis

KW - Percutaneous coronary intervention

KW - Systematic review

UR - http://www.scopus.com/inward/record.url?scp=33751328285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751328285&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2005.11.019

DO - 10.1016/j.ijcard.2005.11.019

M3 - Article

VL - 114

SP - 104

EP - 105

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

IS - 1

ER -